|
Match
|
Document |
Document Title |
|
|
7459429 |
Method of treating disturbances of iron distribution in inflammatory intestinal diseases
The present invention relates to the use of erythropoietin for the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases.
|
|
|
7459439 |
Granulysin peptides and methods of use thereof
Granulysin peptides are small antimicrobial agents with potent activity against bacteria and inflammation. A pharmaceutical composition comprising granulysin peptides as an active agent is...
|
|
|
7459432 |
Modification of feeding behavior
Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist...
|
|
|
7456148 |
Method of producing an anticoagulation effect
A method for producing an anticoagulation effect in a blood coagulation assay, said method comprising contacting a sample of blood with an effective amount of apolipoprotein CIII or fragment,...
|
|
|
7455835 |
Methods for treating immune system diseases using a soluble CTLA4 molecule
The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their...
|
|
|
7456151 |
Promoting angiogenesis with netrin1 polypeptides
The present invention provides methods and compositions for modulating proliferation, differentiation, migration, and adhesion of cardiovascular cell types.
|
|
|
7456146 |
Lytic peptide prodrugs
A cytotoxin can be rendered non-toxic by charge neutralizing the amino acids salient to pore assembly and/or sterically inhibiting formation of the peptide's active conformation. In the presence of...
|
|
|
7456149 |
ALK7 and myostatin inhibitors and uses thereof
The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is...
|
|
|
7456150 |
Pulmonary delivery of active fragments of parathyroid hormone
Systemic delivery of parathyroid hormone to a mammalian host is accomplished by inhalation through the mouth of a dispersion of an N-terminal fragment of PTH. It has been found that such...
|
|
|
7452856 |
Antibacterial peptide
The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or...
|
|
|
7452869 |
NIP3 family of proteins
Methods and compositions for modulating necrosis and for treating neurological and cardiovascular diseases are described. The inventors have shown that BNIP3 is involved in cell necrosis and cell...
|
|
|
7452968 |
Secreted protein factor and cell membrane-bound splice variant
A novel mammalian protein system is disclosed. This system comprises a secreted protein factor and its related membrane-bound splice variant. These novel proteins have no homology to any known...
|
|
|
7452866 |
Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit 1
The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homologous to amino acid residues 130-137 or 132-139 of human troponin...
|
|
|
7452540 |
Enhanced immunization and suppression of oral tolerance
This invention provides for methods of immunizing mammals against tumors expressing a carcinoembryonic antigen using a carcinoembryonic immunogen modified to lack cellular immunosuppressive...
|
|
|
7452970 |
Human endothelin receptor
DNA encoding an endothelin receptor shown in SEQ ID NO: 1 or 2 in the Sequence Listing is isolated from cDNA which is prepared from poly(A) + RNA derived from a human placenta. In addition, an...
|
|
|
7452543 |
Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
A class of novel agents that are able to modify nociceptive afferent function is provided. The agents may inhibit the release of neurotransmitters from discrete populations of neurones and thereby...
|
|
|
7452966 |
GLP-1 analog fusion proteins
The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The...
|
|
|
7452865 |
Antagonistic analogs of GH RH (2003)
There is provided a novel series of synthetic antagonistic analogs of hGH-RH(1-29)NH 2 . These analogs inhibit the activity of endogenous hGH-RH on the pituitary GH-RH receptors, and therefore...
|
|
|
7452863 |
NGF variants
NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of...
|
|
|
7452867 |
Use of ADNF polypeptides for treating peripheral neurotoxicity
This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also...
|
|
|
7452858 |
Treatment of gestational diabetes
Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that...
|
|
|
7452864 |
Use of the cathelicidin LL-37 and derivatives thereof for wound healing
Use of the antimicrobial cathelicidin peptide ll-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of...
|
|
|
7452965 |
Colon tumor specific binding peptides
Phage display was used to screen peptide libraries that distinguish between well-differentiated (HCT116) and poorly-differentiated colon carcinoma cells (HT29). The screening protocol used...
|
|
|
7452538 |
Death domain containing receptor 4 antibodies and methods
The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid...
|
|
|
7449559 |
Truncated EGF receptor
The present invention relates to truncated EGF receptor molecules that exhibit increased binding affinities for EGFR ligands such as EGF and TGF1. The present invention also relates to methods of...
|
|
|
7449200 |
Nanoparticles for protein/peptide delivery and delivery means
The invention discloses the biodegradable nanoparticle for use in nanoparticle projectile bombardment as a carrier for administering proteins or peptides to an animal subject. The nanoparticles are...
|
|
|
7449558 |
Site-specific labelling of proteins
An in vivo method for labelling a protein having an N-terminal cysteine is disclosed. A probe comprising a thioester group and a detectable label is introduced into a cell expressing the N-terminal...
|
|
|
7446091 |
Methods and preparations for curing clinically ill patients
This invention relates to a life saving medicament for critically ill patients and a method of treatment. The composition is a pharmaceutically effective amount of a blood glucose regulator which...
|
|
|
7446089 |
Methods of inhibiting and treating bacterial biofilms by metal chelators
The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron...
|
|
|
7446183 |
Fusion protein comprising growth hormone and growth hormone receptor
This invention relates to agents which bind to cell surface receptors; methods to manufacture said agents; therapeutic compositions comprising said agents; and screening methods to identify novel...
|
|
|
7445772 |
Heterodimeric four helix bundle cytokines
Heterodimeric proteins comprising two helical bundle cytokines are disclosed. One of the polypeptides comprises zsig81 and a second polypeptide which comprises either p19 (aka IL-12A) or p35 (aka...
|
|
|
7445779 |
Methods of modulating IFNy production
Provided are cytokines and methods of modulating activity of the immune system using cytokine agonists and antagonists. Also provided are methods of treatment of immune and proliferative disorders.
|
|
|
7442370 |
Polymer conjugates of mutated neublastin
A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity...
|
|
|
7442767 |
α1D calcium channel expressed in atrium
Novel calcium channel nucleic acids and polypeptides are disclosed herein. Methods of using the novel nucleic acids and polypeptides are also disclosed.
|
|
|
7442685 |
DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and...
|
|
|
7442682 |
Transepithelial delivery of peptides with incretin hormone activities
Compositions and methods are disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is...
|
|
|
7442684 |
Long-acting hormone and growth factor compositions and uses thereof
This invention provides VEGF-FSH compounds having increased serum half-lives relative to either native VEGF or FSH, in which both VEGF and FSH are biologically active. This invention also provides...
|
|
|
7442686 |
Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
The Rho family GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin from Clostridium botulinum , can stimulate regeneration and sprouting of injured axons. The...
|
|
|
7438920 |
Crystals of hepatitis C virus helicase or fragments thereof comprising a helicase binding pocket
The invention relates to the X-ray crystal structure of the hepatitis C virus helicase domain. More specifically, the invention relates to crystallized complexes of HCV helicase and an...
|
|
|
7438921 |
Buttock deformity treatment
Methods for treating a buttock deformity or for preventing development of a buttock deformity by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a buttock...
|
|
|
7439229 |
Cytokine activity regulator molecules from tick salivary glands
The present invention relates to cytokine activity regulator molecules (CARMs) and their use in controlling the action of cytokines, particularly chemokines. In particular, the invention relates to...
|
|
|
7439228 |
Bioactive peptides
The present invention provides a cytotoxic 7 to 25-mer peptide with three or more catonic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides,...
|
|
|
7439224 |
Indications of mannan-binding lectin (MBL) in the treatment of immuno-compromised individuals
The present invention relates to the use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least...
|
|
|
7439230 |
Methods of treatment using CTLA4 mutant molecules
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4...
|
|
|
7435410 |
Methods of treatment with interferson and albumin fusion protein
Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences...
|
|
|
7435419 |
Methods of diagnosing and treating pre-eclampsia or eclampsia
Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia or a propensity to develop pre-eclampsia or eclampsia by detecting the levels of placental growth factor in a subject.
|
|
|
7435719 |
Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
The present invention relates in general to metalloproteinase inhibitors and to polynucleotides encoding such inhibitors. In particular, the invention relates to novel mammalian inhibitors of...
|
|
|
7435869 |
Transgenic nonhuman mammals producing fibrinogen in milk and methods of producing fibrin
A transgenic, non-human mammalian animal is capable of expressing a heterologous gene for human or other recombinant physiologically functional fibrinogen holoprotein or individual subunit chain...
|
|
|
7435718 |
CXCR4 antagonist treatment of hematopoietic cells
In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication,...
|
|
|
7432243 |
Truncated 24kDa basic fibroblast growth factor
The invention relates to fragments of an amino acid sequence of mature, full length 24 kDa fibroblast growth factor-2 or an analog thereof. The fragments have an activity that inhibits the...
|